Novo Nordisk's Buyback Ledger, a Failed Ad Injunction and a New Pediatric Insulin Label All Point to 4 November
Published on 10/28/2026 at 10:01 | Editorial boerse-global.de
Novo Nordisk has spent 11,187,348,102 DKK buying back its own shares under its current programme, the company said on Monday — a figure that speaks to capital allocation rather than to any improvement in the underlying business.
By 23 October the group had repurchased 40,274,179 B shares. The overarching programme authorises up to DKK 15 billion. Monday's disclosure documents purchases already executed, not an intention still outstanding: completed buybacks are a matter of record, whereas the ceiling itself carries no commitment as to when, or on what scale, further purchases will follow.
As of that date Novo Nordisk held 54,314,876 of its own B shares, equal to 1.2% of its share capital. Treasury holdings and shares acquired within the programme are two distinct measures. Either way, the capital return answers a different investor question from the one posed by the drug pipeline — it describes the deployment of cash, while whether business expectations are improving must be shown by operational progress and the next set of figures.
Research access, terms undisclosed
On the research side, Ablexis announced on 14 October a non-exclusive licensing agreement giving Novo Nordisk access to its AlivaMab-Mouse technology for antibody development. Financial terms were not published. The deal is a technology access arrangement, not a reported approval success, and because it is non-exclusive Novo Nordisk gains no exclusive right of use. Investors can read it as a widening of research capability, but not yet as a quantifiable contribution to results.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Valuation sentiment has meanwhile moved the other way. On 19 October HSBC cut its price target to 280 DKK from 320 DKK while reaffirming its "Hold" rating — a cautious counterweight to the buybacks.
A mixed week on regulation and law
Friday brought a regulatory decision: the US Food and Drug Administration approved Awiqli to improve blood-sugar control in children aged ten and older with type 2 diabetes, used alongside diet and exercise. According to Novo Nordisk it is the first once-weekly long-acting basal insulin approved for this patient group.
CagriSema, by contrast, remains an investigational compound, so positive study results must be weighted differently from a granted approval. The CagriSema findings published roughly a week earlier concern a post-hoc analysis of REDEFINE 1; in the placebo arm average weight loss was 3.0%. The analysis was presented at the annual meeting of the Menopause Society.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
On the legal front, Reuters reported that Novo Nordisk on Monday failed in its emergency application against Eli Lilly's advertising for weight-loss medicines. The presiding US judge found the evidence of harm insufficient, and the advertisements may continue while the litigation proceeds. The ruling does not end the dispute — it means Novo Nordisk did not obtain the temporary advertising stop it sought.
The next fixed checkpoint is 4 November 2026, when Novo Nordisk publishes results for the first nine months of 2026. That report will be the economic stocktaking. Developments arising after the reporting period may matter for the future, but they do not retrospectively explain those nine months. Until then, the documented share purchases remain a concrete factor in how capital is being used — they are no substitute for a better operational outlook.
Ad
Novo Nordisk Stock: New Analysis - 28 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
